In the same experimental model of intestinal inflammation using C57BL/6 female mice, esculetin orally administered at 20 mg/Kg ameliorated intestinal injury, decreased MPO activity and IL-6 and TNF-α production, and inhibited NF-κB/MPAKs signaling pathways [82]. Here, MPO is linked to inflammation.